Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: Chance Pharmaceuticals’ CXG87 asthma inhalation therapy filing in China highlights how improved dry powder inhaler design could reshape respiratory drug delivery and asthma control.
Pharma & Biotech

Can Chance Pharma’s asthma inhaler challenge Symbicort’s grip on China’s respiratory market?

Asthma drugs are familiar. Delivery remains the problem. CXG87 could test whether better inhaler engineering changes China’s asthma market.

Read More
Representative image: A subcutaneous Alzheimer’s treatment injector is shown in a clinical consultation setting as Eisai Co., Ltd. and Biogen Inc. await the FDA’s August 2026 decision on Leqembi Iqlik as a starting dose for early Alzheimer’s disease.
Pharma & Biotech

FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy

Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.

Read More
Representative image: Advanced liver cancer imaging and RNA-based oncology research illustrate Rznomics Inc.’s FDA RMAT designation for RZ-001 in hepatocellular carcinoma, highlighting the growing role of RNA editing in next-generation cancer therapy.
Pharma & Biotech

FDA RMAT status puts Rznomics’ RNA editing platform under a brighter clinical spotlight

RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.

Read More
Representative image: Researchers review pancreatic enzyme replacement therapy data in a biotech lab setting, reflecting Blackstone Life Sciences’ $250 million investment in Anagram Therapeutics to advance ANG003 for exocrine pancreatic insufficiency.
Pharma & Biotech

Why Blackstone’s $250m Anagram deal could reshape pancreatic enzyme therapy

PERT is old, essential and burdensome. Blackstone’s $250m Anagram bet asks whether ANG003 can reset enzyme therapy.

Read More
Representative image: Harbour BioMed’s FDA-cleared HBM7004 IND highlights the growing race to develop B7-H4xCD3 bispecific antibodies for advanced solid tumors, as biotech firms test whether next-generation immunotherapies can improve cancer treatment options beyond conventional approaches.
Pharma & Biotech

HBM7004 FDA clearance gives Harbour BioMed a fresh solid tumor immunotherapy test

Solid tumor T-cell engagers still face safety limits. Harbour BioMed’s HBM7004 now tests whether B7-H4 can widen that window.

Read More
Representative image: A clinical consultation for psoriatic arthritis, highlighting how Bristol Myers Squibb’s EU approval of Sotyktu could expand oral treatment options for adults with active inflammatory joint disease.
Pharma & Biotech

Why Bristol Myers Squibb’s Sotyktu approval could reshape the oral psoriatic arthritis race

A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.

Read More
Representative image of an AI-enabled biotechnology lab, illustrating how the LenioBio and Twist Bioscience partnership could accelerate protein expression, wet-lab validation, and next-generation AI drug discovery workflows.
Pharma & Biotech

AI can design proteins faster than labs can test them. LenioBio and Twist want to fix that bottleneck

AI can design proteins fast. Biology still sets the pace. LenioBio and Twist Bioscience are targeting drug discovery’s validation gap.

Read More
Representative image: Traws Pharma’s push into potential hantavirus treatment candidates highlights the growing need for antiviral drug development against rare but severe rodent-borne viral infections.
Pharma & Biotech

Can Traws Pharma turn hantavirus urgency into a credible antiviral program?

Hantavirus has no specific antiviral option. Traws Pharma’s next test is turning outbreak urgency into credible clinical candidates.

Read More
Representative image: Gilead Sciences’ HIV drug growth helped lift its Q1 performance, highlighting how Biktarvy, Descovy and long-acting prevention therapies remain central to the company’s biopharma growth story.
Pharma & Biotech

Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished

Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.

Read More
Representative image: Citius Oncology’s Lymphir commercialisation push highlights the growing pressure on rare cancer biotech firms to turn FDA approvals and fresh funding into real-world treatment adoption.
Pharma & Biotech

Citius Oncology raises $36.5m, but can Lymphir convert rare cancer approval into commercial traction?

Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.

Read More